SLC5A2 and type 2 diabetes mellitus: A meta-analysis of the data from three major CVOTs (the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients—Removing Excess Glucose [EMPA-REG OUTCOME], CANVAS, and DECLARE-TIMI 58) with SGLT2 inhibitors in patients with T2D, revealed a robust reduction in the risk of AKI by 34%; however, these events were nonadjudicated [48].